Animal models for dicarboxylic aciduria

Area of Science:

• Biochemistry
• Metabolic Disorders
• Pharmacology

Background:

• Mitochondrial beta-oxidation is crucial for energy metabolism.
• Impaired beta-oxidation can lead to dicarboxylic aciduria, a marker in certain metabolic diseases.
• Acyl-CoA esters play a role in fatty acid metabolism.

Purpose of the Study:

• To investigate the mechanisms by which four compounds (POCA, pent-4-enoate, hypoglycin, valproate) inhibit mitochondrial beta-oxidation.
• To explore the role of these compounds in inducing dicarboxylic aciduria.
• To establish animal models for studying dicarboxylic aciduria and inborn errors of metabolism.

Main Methods:

• Administration of four hypoglycaemic compounds to fasted animals.
• Analysis of acyl-CoA ester formation in vivo.
• Assessment of mitochondrial beta-oxidation inhibition.
• Monitoring for the induction of dicarboxylic aciduria.

Main Results:

• The four compounds, including 2[5(4-chlorophenyl)pentyl] oxirane-2-carboxylate (POCA), hypoglycin, and valproate, inhibit mitochondrial beta-oxidation through distinct mechanisms.
• POCA, hypoglycin, and valproate were observed to induce dicarboxylic aciduria.
• Saturated dicarboxylic acids are likely formed via peroxisomal beta-oxidation when mitochondrial pathways are compromised.

Conclusions:

• These inhibitors serve as valuable tools for creating animal models of dicarboxylic aciduria.
• The findings contribute to understanding the pathophysiology of inborn errors of metabolism affecting fatty acid oxidation.
• Differential inhibition of mitochondrial beta-oxidation by these compounds highlights complex metabolic regulation.